Trial Profile
A Phase 2, Multi-center, Prospective, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effectiveness and Safety of SYM-1219 for the Treatment of Women With Bacterial Vaginosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Nov 2020
Price :
$35
*
At a glance
- Drugs Secnidazole (Primary)
- Indications Bacterial infections; Bacterial vaginosis
- Focus Registrational; Therapeutic Use
- Sponsors Symbiomix Therapeutics
- 18 Sep 2017 According to a Symbiomix Therapeutics media release, the US FDA has approved Solosec (secnidazole) 2g oral granules for the treatment of bacterial vaginosis (BV) in adult women.
- 01 Aug 2017 Results published in the Obstetrics and Gynecology
- 17 Jul 2017 Results published in the Symbiomix Therapeutics media release.